NEWTON, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Dynasil Corporation of America (NASDAQ: DYSL), a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced third quarter fiscal 2019 results.

Third Quarter Fiscal 2019 Results

Consolidated revenue was $11.1 million for the three months ended June 30, 2019. This $0.6 million or 5% revenue increase over the quarter ended June 30, 2018 resulted from an 18% increase in Innovations and Development segment revenue, which was partially offset by a 4% decrease in Optics segment revenue.

Gross profit for the quarter ended June 30, 2019 was $4.1 million, or 37% of revenue, as compared to the gross profit of $4.2 million, or 40% of revenue for the quarter ended June 30, 2018.

Total operating expenses were $4.3 million for the three-month period ended June 30, 2019, a 19% increase over the $3.6 million in operating expenses for the three months ended June 30, 2018. The increase was attributable to $0.5 million expended in the Company’s efforts to delist from The Nasdaq Stock Market, as well as increased recruitment and personnel expenses as the Company continues to fill key positions.

Income (loss) from operations for the quarter ended June 30, 2019 was a loss of ($0.1) million, compared with income from operations of $0.6 million for the quarter ended June 30, 2018.

Certain key metrics by segment for the current quarter and the same quarter last year are presented below:

 
Results of Operations for the Three Months Ended June 30, 2019
  Optics  Innovation and
Development*
  Biomedical  Total 
Revenue$  5,899,000 $  5,191,000 $  -  $  11,090,000 
Gross profit   2,112,000    1,994,000    -     4,106,000 
GM %   36%   38%   -     37%
Operating expenses   2,237,000    1,992,000     23,000    4,252,000 
Operating income (loss)$   (125,000)$  2,000 $   (23,000)$   (146,000)
     
Results of Operations for the Three Months Ended June 30, 2018
 OpticsInnovation and
Development*
BiomedicalTotal
Revenue$  6,159,000 $   4,383,000 $  -  $  10,542,000 
Gross profit   2,299,000    1,876,000     -      4,175,000 
GM %   37%   43%    -     40%
Operating expenses    1,721,000    1,760,000     84,000    3,565,000 
Operating income (loss)$     578,000 $    116,000 $    (84,000)$     610,000 
     
*Formerly Contract Research    
    

Net income for the three months ended June 30, 2019 was loss of ($0.3) million, or ($0.02) per share, as compared to income of $0.4 million, or $0.02 per share for the quarters ended June 30, 2019 and 2018, respectively, largely as a result of the increased expenses in the fiscal year 2019.  The provision for income taxes for the third quarter of 2019 was approximately $0.1 million, whereas, during the quarter ended June 30, 2018, the Company had a tax provision of $0.2 million.

Plan to Deregister and Delist the Common Stock

As previously announced, on August 7, 2019, the Company completed a stockholder-approved transaction whereby the Company effected a reverse stock split of its common stock followed immediately by a forward stock split of its common stock. As a result of the Transaction, based on information provided to the Company by its transfer agent, Continental Stock Transfer & Trust Company, and the Depository Trust Company (DTC), 2,825,268 pre-split shares of common stock are due to be exchanged for cash, and the aggregate amount payable by the Company to the former holders of such shares is approximately $3,249,000. The transaction was completed as part of the Company’s plan to terminate the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended, and suspend the Company’s duty to file periodic reports and other information with the Securities and Exchange Commission and delist the Company’s common stock from the Nasdaq Capital Market.   The Company has notified the Nasdaq Stock Market of its intent to voluntarily delist its common stock and to withdraw the registration of its common stock with the Securities and Exchange Commission. The Company expects that listing of its shares on the Nasdaq Capital Market will be terminated on or about August 29, 2019, at which time the Company intends to file a Form 15 with the SEC to suspend the Company’s reporting obligations under Section 15(d) of the Exchange Act.

As a result, the Company will not be hosting a quarterly conference call with respect to its third quarter fiscal 2019 results. 

About Dynasil

Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures optics and photonics products, optical detection and analysis technology and optical components for the homeland security, medical and industrial markets.  Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is selling and continuing to develop products for dual-mode radiation detection solutions for security and commercial applications and sensors for non-destructive testing.  Dynasil has an impressive and growing portfolio of issued and pending U.S. patents.  The Company is based in Newton, Massachusetts, with additional operations in Massachusetts, New Jersey, New York and the United Kingdom. More information about the Company is available at www.dynasil.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, our compliance with the financial covenants under our loan agreements with Middlesex Savings Bank and Massachusetts Capital Resource Company, our expectations regarding results of operations, the commercialization of our technology, including the Xcede patch and our dual mode detectors, the success of efforts to develop a successful Xcede Patch and to fund that development, our development of new technologies including at Dynasil Biomedical, the adequacy of our current financing sources to fund our current operations, our growth initiatives, our capital expenditures, the strength of our intellectual property portfolio, statements about the timing and effectiveness of the reverse and forward stock splits, the deregistration and delisting of the Company’s common stock and the perceived benefits and costs of the proposed transaction. These forward-looking statements may be identified by the use of words such as “plans,” “intends,” “may,” “could,” “expect,” “estimate,” “anticipate,” “continue,” or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward looking statements could differ materially from those stated in such forward looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, Xcede’s ability to produce preclinical data sufficient to enable it to initiate clinical studies of hemostatic patch, clinical results of Xcede’s programs which may not support further development, the ability of our RMD business unit to identify and pursue possible continued development opportunities for the Xcede patch, which is not assured, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to deleverage our balance sheet, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, seasonality, the many variables that may impact the Company’s projected cost savings, variables and risks related to the stock split transaction, SEC regulatory review of the Company’s filings related to the such transaction, and the continuing determination of the Board of Directors and Special Committee that such transaction is in the best interests of all stockholders, as well as the uncertainties set forth in the Company’s Annual Report on Form 10-K, filed on December 21, 2018, including the risk factors contained in Item 1A, and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. 

 
Dynasil Corporation of America and Subsidiaries
Consolidated Balance Sheets (Unaudited)
    
ASSETSJune 30, 2019 September 30, 2018
Current Assets   
  Cash and cash equivalents$  519,000 $  2,327,000
  Accounts receivable, net   5,347,000    4,069,000
  Unbilled receivables   2,422,000    1,214,000
  Contract assets    62,000  1,000
  Inventories, net of reserves   4,544,000    4,106,000
  Prepaid expenses and other current assets   717,000    664,000
  Total current assets   13,611,000    12,381,000
    
Property, Plant and Equipment, net   7,762,000    8,098,000
Other Assets   
  Intangibles, net   665,000    755,000
  Deferred tax asset   4,128,000    4,333,000
  Goodwill   5,864,000    5,900,000
  Long term contract assets    7,000    7,000
  Security deposits   53,000    58,000
  Total other assets   10,717,000    11,053,000
    
  Total Assets$  32,090,000 $  31,532,000
    
LIABILITIES AND STOCKHOLDERS' EQUITY   
Current Liabilities   
  Equipment line of credit$  961,000 $  - 
  Current portion of long-term debt   1,431,000    1,246,000
  Capital lease obligations, current    33,000    40,000
  Accounts payable   2,544,000    2,355,000
  Contract liabilities    33,000    253,000
  Accrued expenses and other liabilities    2,667,000    2,803,000
  Total current liabilities   7,669,000    6,697,000
    
Long-term Liabilities   
  Long-term debt   1,797,000    2,075,000
  Long-term capital lease obligations    30,000    52,000
  Deferred tax liability    200,000    205,000
  Other long-term liabilities    181,000    175,000
  Total long-term liabilities   2,208,000    2,507,000
    
Stockholders' Equity   
  Dynasil stockholders' equity   20,943,000    21,029,000
  Noncontrolling interest   1,270,000    1,299,000
  Total stockholders' equity   22,213,000    22,328,000
    
Total Liabilities and Stockholders' Equity$  32,090,000 $  31,532,000
      

Dynasil Corporation of America
Consolidated Statement of Operations and Comprehensive Income (Loss)
(Unaudited)

  Three Months Ended Nine Months Ended
  June 30, June 30,
   2019  2018   2019  2018 
Net revenue$   11,090,000 $  10,542,000  $  32,650,000 $   29,985,000 
Cost of revenue   6,984,000    6,367,000     20,494,000    18,326,000 
Gross profit   4,106,000     4,175,000     12,156,000    11,659,000 
Operating expenses:     
 Sales and marketing    425,000     288,000     1,300,000    955,000 
 Research and development   162,000    177,000     486,000    701,000 
 General and administrative   3,665,000    3,100,000     10,317,000    9,519,000 
       
Total operating expenses   4,252,000    3,565,000     12,103,000    11,175,000 
Income (loss) from operations   (146,000)   610,000      53,000     484,000 
Interest expense, net   56,000    44,000     144,000    132,000 
Income (loss) before taxes   (202,000)   566,000     (91,000)    352,000 
Income tax (benefit)   66,000    190,000      207,000     (404,000)
Net income (loss)   (268,000)    376,000     (298,000)   756,000 
 Less: Net loss attributable to noncontrolling interest   (5,000)   (15,000)    (18,000)   (124,000)
Net income (loss) attributable to common stockholders$   (263,000)$   391,000  $  (280,000)$   880,000 
       
       
Net income (loss)$   (268,000)$   376,000  $  (298,000)$   756,000 
Other comprehensive income (loss):     
 Foreign currency translation   (136,000)   (384,000)    (132,000)   (127,000)
Total comprehensive income (loss)   (404,000)    (8,000)    (430,000)   629,000 
 Less: comprehensive income (loss)     
 attributable to noncontrolling interest   (5,000)   (15,000)    (18,000)   (124,000)
Total comprehensive income (loss)     
attributable to common stockholders$  (399,000)$   7,000  $   (412,000)$   753,000 
       
Basic net income (loss) per common share$   (0.02)$  0.02  $   (0.02)$  0.05 
Diluted net income (loss) per common share$  (0.02)$  0.02  $   (0.02)$  0.05 
       
Weighted average shares outstanding     
 Basic   17,522,644    17,203,965      17,426,316    17,127,834 
 Diluted   17,522,644     17,221,199     17,426,316    17,147,228 
               

Contact:                                                                                                       
Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: 617.668.6855
pkehe@dynasil.com